Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Exp Neurol ; 321: 113041, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31445043

RESUMEN

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a genetic motor neuron disease affecting infants. This condition is caused by mutations in the IGHMBP2 gene and currently has no cure. Stem cell transplantation is a potential therapeutic strategy for motor neuron diseases such as SMARD1, exerting beneficial effects both by replacing cells and by providing support to endogenous motor neurons. In this work, we demonstrate that human induced pluripotent stem cell (iPSC)-derived neural stem cells (NSCs) selected for the expression of specific markers, namely, Lewis X, CXCR4 and beta 1 integrin, and pretreated with neurotrophic factors and apoptosis/necroptosis inhibitors were able to effectively migrate and engraft into the host parenchyma after administration into the cerebrospinal fluid in a SMARD1 mouse model. We were able to detect donor cells in the ventral horn of the spinal cord and observe improvements in neuropathological features, particularly preservation of the integrity of the motor unit, that were correlated with amelioration of the SMARD1 disease phenotype in terms of neuromuscular function and lifespan. This minimally invasive stem cell approach can confer major advantages in the context of cell-mediated therapy for patients with neurodegenerative diseases.


Asunto(s)
Atrofia Muscular Espinal , Células-Madre Neurales/trasplante , Síndrome de Dificultad Respiratoria del Recién Nacido , Trasplante de Células Madre/métodos , Animales , Modelos Animales de Enfermedad , Humanos , Células Madre Pluripotentes Inducidas/trasplante , Ratones , Fenotipo
2.
Brain ; 142(2): 276-294, 2019 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-30649277

RESUMEN

Spinal muscular atrophy is a motor neuron disorder caused by mutations in SMN1. The reasons for the selective vulnerability of motor neurons linked to SMN (encoded by SMN1) reduction remain unclear. Therefore, we performed deep RNA sequencing on human spinal muscular atrophy motor neurons to detect specific altered gene splicing/expression and to identify the presence of a common sequence motif in these genes. Many deregulated genes, such as the neurexin and synaptotagmin families, are implicated in critical motor neuron functions. Motif-enrichment analyses of differentially expressed/spliced genes, including neurexin2 (NRXN2), revealed a common motif, motif 7, which is a target of SYNCRIP. Interestingly, SYNCRIP interacts only with full-length SMN, binding and modulating several motor neuron transcripts, including SMN itself. SYNCRIP overexpression rescued spinal muscular atrophy motor neurons, due to the subsequent increase in SMN and their downstream target NRXN2 through a positive loop mechanism and ameliorated SMN-loss-related pathological phenotypes in Caenorhabditis elegans and mouse models. SMN/SYNCRIP complex through motif 7 may account for selective motor neuron degeneration and represent a potential therapeutic target.


Asunto(s)
Ribonucleoproteínas Nucleares Heterogéneas/genética , Neuronas Motoras/fisiología , Atrofia Muscular Espinal/genética , Motivos de Nucleótidos/genética , Análisis de Secuencia de ARN/métodos , Proteína 1 para la Supervivencia de la Neurona Motora/genética , Animales , Caenorhabditis elegans , Línea Celular Tumoral , Supervivencia Celular/fisiología , Humanos , Células Madre Pluripotentes Inducidas/patología , Células Madre Pluripotentes Inducidas/fisiología , Ratones , Ratones Transgénicos , Neuronas Motoras/patología , Atrofia Muscular Espinal/patología , ARN/genética
3.
Front Cell Neurosci ; 12: 61, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29559895

RESUMEN

Pathogenic conditions involving degeneration of spinal motor neurons (MNs), such as amyotrophic lateral sclerosis, sarcopenia, and spinal cord injury, mostly occur in individuals whose spinal MNs are fully mature. There is currently no effective treatment to prevent death or promote axonal regeneration of the spinal MNs affected in these patients. To increase our understanding and find a cure for such conditions, easily controllable and monitorable cell culture models allow for a better dissection of certain molecular and cellular events that cannot be teased apart in whole organism models. To date, various types of spinal MN cultures have been described. Yet these models are all based on the use of immature neurons or neurons uncharacterized for their degree of maturity after being isolated and cultured. Additionally, studying only MNs cannot give a comprehensive and complete view of the neurodegenerative processes usually involving other cell types. To date, there is no confirmed in vitro model faithfully emulating disease or injury of the mature spinal MNs. In this review, we summarize the different limitations of currently available culture models, and discuss the challenges that have to be overcome for developing more reliable and translational platforms for the in vitro study of spinal MN degeneration.

4.
Hum Mol Genet ; 25(15): 3152-3163, 2016 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-27270413

RESUMEN

Amyotrophic lateral sclerosis (ALS) is a fatal incurable neurodegenerative disease characterized by progressive degeneration of motor neurons (MNs), leading to relentless muscle paralysis. In the early stage of the disease, MN loss and consequent muscle denervation are compensated by axonal sprouting and reinnervation by the remaining MNs, but this mechanism is insufficient in the long term. Here, we demonstrate that induced pluripotent stem cell-derived neural stem cells (NSCs), in particular the subpopulation positive for LewisX-CXCR4-ß1-integrin, enhance neuronal survival and axonal growth of human ALS-derived MNs co-cultured with toxic ALS astrocytes, acting on both autonomous and non-autonomous ALS disease features. Transplantation of this NSC fraction into transgenic SOD1G93A ALS mice protects MNs in vivo, promoting their ability to maintain neuromuscular junction integrity, inducing novel axonal sprouting and reducing macro- and microgliosis. These effects result in a significant increase in survival and an improved neuromuscular phenotype in transplanted SOD1G93A mice. Our findings suggest that effective protection of MN functional innervation can be achieved by modulation of multiple dysregulated cellular and molecular pathways in both MNs and glial cells. These pathways must be considered in designing therapeutic strategies for ALS patients.


Asunto(s)
Esclerosis Amiotrófica Lateral , Células Madre Pluripotentes Inducidas/metabolismo , Integrina beta1/metabolismo , Antígeno Lewis X/metabolismo , Células-Madre Neurales , Receptores de Interleucina-8A/metabolismo , Trasplante de Células Madre , Superóxido Dismutasa , Aloinjertos , Esclerosis Amiotrófica Lateral/genética , Esclerosis Amiotrófica Lateral/metabolismo , Esclerosis Amiotrófica Lateral/terapia , Animales , Línea Celular , Modelos Animales de Enfermedad , Humanos , Integrina beta1/genética , Antígeno Lewis X/genética , Ratones , Ratones Transgénicos , Neuronas Motoras , Músculo Esquelético , Células-Madre Neurales/metabolismo , Células-Madre Neurales/trasplante , Receptores de Interleucina-8A/genética , Superóxido Dismutasa/biosíntesis , Superóxido Dismutasa/genética
5.
Cell Mol Life Sci ; 73(5): 1003-20, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26681261

RESUMEN

Spinal muscular atrophy (SMA) is a genetic neurological disease that causes infant mortality; no effective therapies are currently available. SMA is due to homozygous mutations and/or deletions in the survival motor neuron 1 gene and subsequent reduction of the SMN protein, leading to the death of motor neurons. However, there is increasing evidence that in addition to motor neurons, other cell types are contributing to SMA pathology. In this review, we will discuss the involvement of non-motor neuronal cells, located both inside and outside the central nervous system, in disease onset and progression. Even if SMN restoration in motor neurons is needed, it has been shown that optimal phenotypic amelioration in animal models of SMA requires a more widespread SMN correction. It has been demonstrated that non-motor neuronal cells are also involved in disease pathogenesis and could have important therapeutic implications. For these reasons it will be crucial to take this evidence into account for the clinical translation of the novel therapeutic approaches.


Asunto(s)
Células Musculares/patología , Atrofia Muscular Espinal/patología , Atrofia Muscular Espinal/terapia , Neuroglía/patología , Neuronas/patología , Células de Schwann/patología , Animales , Huesos/patología , Humanos , Sistema Inmunológico/patología , Hígado/patología , Neuronas Motoras/patología , Atrofia Muscular Espinal/complicaciones , Miocardio/patología , Páncreas/patología
6.
Clin Ther ; 37(3): 668-80, 2015 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-25666449

RESUMEN

PURPOSE: Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in adults. It is almost invariably lethal within a few years after the onset of symptoms. No effective treatment is currently available beyond supportive care and riluzole, a putative glutamate release blocker linked to modestly prolonged survival. This review provides a general overview of preclinical and clinical advances during recent years and summarizes the literature regarding emerging therapeutic approaches, focusing on their molecular targets. METHODS: A systematic literature review of PubMed was performed, identifying key clinical trials involving molecular therapies for ALS. In addition, the ALS Therapy Development Institute website was carefully analyzed, and a selection of ALS clinical trials registered at ClinicalTrials.gov has been included. FINDINGS: In the last several years, strategies have been developed to understand both the genetic and molecular mechanisms of ALS. Several therapeutic targets have been actively pursued, including kinases, inflammation inhibitors, silencing of key genes, and modulation or replacement of specific cell populations. The majority of ongoing clinical trials are investigating the safety profiles and tolerability of pharmacologic, gene, and cellular therapies, and have begun to assess their effects on ALS progression. IMPLICATIONS: Currently, no therapeutic effort seems to be efficient, but recent findings in ALS could help accelerate the discovery of an effective treatment for this disease.


Asunto(s)
Esclerosis Amiotrófica Lateral/terapia , Riluzol/uso terapéutico , Adulto , Esclerosis Amiotrófica Lateral/fisiopatología , Progresión de la Enfermedad , Humanos , Resultado del Tratamiento
7.
Stem Cell Reports ; 3(2): 297-311, 2014 Aug 12.
Artículo en Inglés | MEDLINE | ID: mdl-25254343

RESUMEN

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a motor neuron disease caused by mutations in the IGHMBP2 gene, without a cure. Here, we demonstrate that neural stem cells (NSCs) from human-induced pluripotent stem cells (iPSCs) have therapeutic potential in the context of SMARD1. We show that upon transplantation NSCs can appropriately engraft and differentiate in the spinal cord of SMARD1 animals, ameliorating their phenotype, by protecting their endogenous motor neurons. To evaluate the effect of NSCs in the context of human disease, we generated human SMARD1-iPSCs motor neurons that had a significantly reduced survival and axon length. Notably, the coculture with NSCs ameliorate these disease features, an effect attributable to the production of neurotrophic factors and their dual inhibition of GSK-3 and HGK kinases. Our data support the role of iPSC as SMARD1 disease model and their translational potential for therapies in motor neuron disorders.


Asunto(s)
Células Madre Pluripotentes Inducidas/citología , Células-Madre Neurales/citología , Proteínas Serina-Treonina Quinasas/metabolismo , Animales , Axones/metabolismo , Diferenciación Celular , Linaje de la Célula , Técnicas de Cocultivo , Modelos Animales de Enfermedad , Glucógeno Sintasa Quinasa 3/antagonistas & inhibidores , Glucógeno Sintasa Quinasa 3/metabolismo , Humanos , Estimación de Kaplan-Meier , Ratones , Neuronas Motoras/citología , Neuronas Motoras/metabolismo , Atrofia Muscular Espinal/mortalidad , Atrofia Muscular Espinal/terapia , Factores de Crecimiento Nervioso/metabolismo , Células-Madre Neurales/trasplante , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Síndrome de Dificultad Respiratoria del Recién Nacido/mortalidad , Síndrome de Dificultad Respiratoria del Recién Nacido/terapia , Trasplante Heterólogo
8.
Stem Cell Res Ther ; 5(4): 87, 2014 Jul 14.
Artículo en Inglés | MEDLINE | ID: mdl-25157556

RESUMEN

Motor neurons are cells located in specific areas of the central nervous system, such as brain cortex (upper motor neurons), brain stem, and spinal cord (lower motor neurons), which maintain control over voluntary actions. Motor neurons are affected primarily by a wide spectrum of neurological disorders, generally indicated as motor neuron diseases (MNDs): these disorders share symptoms related to muscular atrophy and paralysis leading to death. No effective treatments are currently available. Stem cell-derived motor neurons represent a promising research tool in disease modeling, drug screening, and development of therapeutic approaches for MNDs and spinal cord injuries. Directed differentiation of human pluripotent stem cells - human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) - toward specific lineages is the first crucial step in order to extensively employ these cells in early human development investigation and potential clinical applications. Induced pluripotent stem cells (iPSCs) can be generated from patients' own somatic cells (for example, fibroblasts) by reprogramming them with specific factors. They can be considered embryonic stem cell-like cells, which express stem cell markers and have the ability to give rise to all three germ layers, bypassing the ethical concerns. Thus, hiPSCs constitute an appealing alternative source of motor neurons. These motor neurons might be a great research tool, creating a model for investigating the cellular and molecular interactions underlying early human brain development and pathologies during neurodegeneration. Patient-specific iPSCs may also provide the premises for autologous cell replacement therapies without related risks of immune rejection. Here, we review the most recent reported methods by which hESCs or iPSCs can be differentiated toward functional motor neurons with an overview on the potential clinical applications.


Asunto(s)
Técnicas de Cultivo de Célula , Células Madre Embrionarias/citología , Células Madre Pluripotentes Inducidas/citología , Neuronas Motoras/citología , Biomarcadores/metabolismo , Diferenciación Celular , Humanos
9.
Prog Neurobiol ; 114: 15-24, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24246715

RESUMEN

Developmental studies and experimental data have enabled us to assert that the terminal cell differentiation state is reversible, and that altering the balance of specific transcription factors could be a powerful strategy for inducing pluripotency. Due to the risks related to using induced pluripotent cells in clinical applications, biologists are now striving to develop methods to induce a committed differentiated cell type by direct conversion of another cell line. Several reprogramming factors have been discovered, and some cellular phenotypes have been obtained by novel transdifferentiation processes. It has been recently demonstrated that induced neural stem cells (iNSCs) can be obtained from rodent and human somatic cells, like fibroblasts, through the forced expression of defined transcription factors. To date, two different approaches have been successfully used to obtain iNSCs: a direct method and an indirect method that involves an intermediate destabilized state. The possibility to induce characterized iNSCs from human cells, e.g. fibroblasts, has opened new horizons for research in human disease modelling and cellular therapeutic applications in the neurological field. This review focuses on reported reprogramming techniques and innovative techniques that can be further explored in this area, as well as on the criteria for the phenotypic characterization of iNSCs and their use in developing novel therapeutic strategies for neurological diseases.


Asunto(s)
Encefalopatías/terapia , Diferenciación Celular , Células-Madre Neurales/fisiología , Células-Madre Neurales/trasplante , Animales , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA